Pharmaceuticals, Biotechnology & Life Sciences

Incyte reveals breakthrough Phase‑1 oncology data at ESMO 2026 and partners with Halozyme to develop subcutaneous delivery of INCA033989, boosting patient access.

Celldex Therapeutics: Exploring immune‑based therapies for cancer, autoimmune, and cardiovascular diseases, backed by robust R&D and a $2.8 billion market cap.

Inmune Bio: La Jolla‑based biotech on a cancer‑therapy mission, rising Nasdaq price, promising pipeline, and patient‑centric breakthroughs.

Greenwich Lifesciences revamps FLAMINGO‑01 breast‑cancer vaccine trial—broader enrollment, new endpoints, and digital tracking—while shares drop, highlighting market reaction to design changes.

Samsung Biologics’ all‑cash tender offer for PolyPeptide Group AG boosts its peptide‑API expertise, expanding global CDMO services and growth prospects.

Harbin Pharmaceutical’s 58% July rally shows how solid earnings and a diversified drug portfolio can outshine a tech sell‑off, offering investors a resilient growth option.

REVOLUTION Medicines (RVMD) leads oncology with novel targeted therapies, strong ETF inclusion, and a “strong buy” rating, signaling high-growth potential for investors.

Hyperliquid’s HYPE token surges past $30, tops Dogecoin’s market value, and outpaces XRP’s futures interest amid a volatile crypto market—find out why institutional whales and treasury strategy fuel this momentum.

REGENXBIO raises $100M amid breakthrough 5‑year data for its gene‑therapy for wet AMD and diabetic retinopathy—boosting investor confidence.

Greenwich Lifesciences expands FLAMINGO‑01 Europe enrollment, gaining EMA approval to combine HLA‑A02:01 and HLA‑A24:02, boosting oncology trial power and investor appeal.